Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Further delineation of the clinical spectrum of White–Sutton syndrome: 12 new individuals and a review of the literature

Abstract

White–Sutton syndrome (WHSUS) is a neurodevelopmental disorder caused by heterozygous loss-of-function variants in POGZ. Through the Deciphering Developmental Disorders study and clinical testing, we identified 12 individuals from 10 families with pathogenic or likely pathogenic variants in POGZ (eight de novo and two inherited). Most individuals had delayed development and/or intellectual disability. We analyzed the clinical findings in our series and combined it with data from 89 previously reported individuals. The results demonstrate WHSUS is associated with variable developmental delay or intellectual disability, increased risk of obesity, visual defects, craniofacial dysmorphism, sensorineural hearing loss, feeding problems, seizures, and structural brain malformations. Our series includes further individuals with rod-cone dystrophy, cleft lip and palate, congenital diaphragmatic hernia, and duplicated renal drainage system, suggesting these are rare complications of WHSUS. In addition, we describe an individual with a novel, de novo missense variant in POGZ and features of WHSUS. Our work further delineates the phenotypic spectrum of WHSUS highlighting the variable severity of this disorder and the observation of familial pathogenic POGZ variants.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Exon and protein models of POGZ showing location of the variants.
Fig. 2: Photographs of three individuals with POGZ variants.

References

  1. 1.

    Stessman HAF, Willemsen MH, Fenckova M, Penn O, Hoischen A, Xiong B, et al. Disruption of POGZ is associated with intellectual disability and autism spectrum disorders. Am J Hum Genet. 2016;98:541–52.

    CAS  Article  Google Scholar 

  2. 2.

    White J, Beck CR, Harel T, Posey JE, Jhangiani SN, Tang S, et al. POGZ truncating alleles cause syndromic intellectual disability. Genome Med. 2016;8:3.

    Article  Google Scholar 

  3. 3.

    Dentici ML, Niceta M, Pantaleoni F, Barresi S, Bencivenga P, Dallapiccola B, et al. Expanding the phenotypic spectrum of truncating POGZ mutations: association with CNS malformations, skeletal abnormalities, and distinctive facial dysmorphism. Am J Med Genet A 2017;173:1965–9.

    CAS  Article  Google Scholar 

  4. 4.

    Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014;511:344–7.

    CAS  Article  Google Scholar 

  5. 5.

    Lelieveld SH, Reijnders MRF, Pfundt R, Yntema HG, Kamsteeg E-J, de Vries P, et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat Neurosci. 2016;19:1194–6.

    CAS  Article  Google Scholar 

  6. 6.

    Ferretti A, Barresi S, Trivisano M, Ciolfi A, Dentici ML, Radio FC, et al. POGZ-related epilepsy: case report and review of the literature. Am J Med Genet A 2019;179:1631–6.

    PubMed  Google Scholar 

  7. 7.

    Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–8.

    Article  Google Scholar 

  8. 8.

    Samanta D, Ramakrishnaiah R, Schaefer B. The neurological aspects related to POGZ mutation: case report and review of CNS malformations and epilepsy. Acta Neurol Belg. 2019;120:447–50.

  9. 9.

    Pascolini G, Agolini E, Fleischer N, Gulotta E, Cesario C, D’Elia G, et al. A novel patient with White-Sutton syndrome refines the mutational and clinical repertoire of the POGZ-related phenotype and suggests further observations. Am J Med Genet A. 2020;182:1791–5.

    CAS  Article  Google Scholar 

  10. 10.

    Assia Batzir N, Posey JE, Song X, Akdemir ZC, Rosenfeld JA, Brown CW, et al. Phenotypic expansion of POGZ-related intellectual disability syndrome (White-Sutton syndrome). Am J Med Genet A. 2020;182:38–52.

    CAS  Article  Google Scholar 

  11. 11.

    Garde A, Cornaton J, Sorlin A, Moutton S, Nicolas C, Juif C, et al. Neuropsychological study in 19 French patients with White-Sutton syndrome and POGZ mutations. Clin Genet. 2021;99:407–17.

    CAS  Article  Google Scholar 

  12. 12.

    Dal S, Hopper B, du Chattel MVR, Goel H A case of White-Sutton syndrome with previously described loss-of-function variant in DDE domain of POGZ (p.Arg1211*) and Kartagener syndrome. Am J Med Genet A. 2020;185:1006–7.

  13. 13.

    Nozawa R-S, Nagao K, Masuda H-T, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation. Nat Cell Biol. 2010;12:719–27.

    CAS  Article  Google Scholar 

  14. 14.

    Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, et al. Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes. Nat Commun. 2020;11:859.

    CAS  Article  Google Scholar 

  15. 15.

    Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.

    CAS  Article  Google Scholar 

  16. 16.

    Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.

    CAS  Article  Google Scholar 

  17. 17.

    Fukai R, Hiraki Y, Yofune H, Tsurusaki Y, Nakashima M, Saitsu H, et al. A case of autism spectrum disorder arising from a de novo missense mutation in POGZ. J Hum Genet. 2015;60:277–9.

    CAS  Article  Google Scholar 

  18. 18.

    Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–99.

    CAS  Article  Google Scholar 

  19. 19.

    Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–84.

    CAS  Article  Google Scholar 

  20. 20.

    De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional, and chromatin genes disrupted in autism. Nature. 2014;515:209–15.

    Article  Google Scholar 

  21. 21.

    Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 2015;519:223–8.

    Article  Google Scholar 

  22. 22.

    Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet Lond Engl. 2015;385:1305–14.

    Article  Google Scholar 

  23. 23.

    Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources. Am J Hum Genet. 2009;84:524–33.

    CAS  Article  Google Scholar 

  24. 24.

    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med J Am Coll Med Genet. 2015;17:405–24.

    Google Scholar 

  25. 25.

    Ellard S Best Practice Guidelines. The Association for Clinical Genomic Science. 2020. https://www.acgs.uk.com/quality/best-practice-guidelines/

  26. 26.

    Longoni M, High FA, Qi H, Joy MP, Hila R, Coletti CM, et al. Genome-wide enrichment of damaging de novo variants in patients with isolated and complex Congenital Diaphragmatic Hernia. Hum Genet. 2017;136:679–91.

    CAS  Article  Google Scholar 

  27. 27.

    Cheutin T, McNairn AJ, Jenuwein T, Gilbert DM, Singh PB, Misteli T. Maintenance of stable heterochromatin domains by dynamic HP1 binding. Science 2003;299:721–5.

    CAS  Article  Google Scholar 

  28. 28.

    Motamedi MR, Hong E-JE, Li X, Gerber S, Denison C, Gygi S, et al. HP1 proteins form distinct complexes and mediate heterochromatic gene silencing by nonoverlapping mechanisms. Mol Cell. 2008;32:778–90.

    CAS  Article  Google Scholar 

  29. 29.

    Isidor B, Küry S, Rosenfeld JA, Besnard T, Schmitt S, Joss S, et al. De Novo Truncating Mutations in the Kinetochore-Microtubules Attachment Gene CHAMP1 Cause Syndromic Intellectual Disability. Hum Mutat. 2016;37:354–8.

    CAS  Article  Google Scholar 

  30. 30.

    Hempel M, Cremer K, Ockeloen CW, Lichtenbelt KD, Herkert JC, Denecke J, et al. De Novo Mutations in CHAMP1 Cause Intellectual Disability with Severe Speech Impairment. Am J Hum Genet. 2015;97:493–500.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We would like to thank the patients, families and clinicians who have contributed to this report. AEF was supported by the Wales Gene Park. Wales Gene Park is a Health and Care Research Wales funded infrastructure support group. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1 009-003]. This study makes use of DECIPHER (http://decipher.sanger.ac.uk), which is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement. Clinical testing and analysis were performed by The Department of Medical Genetics, Telemark Hospital Trust, Skien, Norway and the Exeter Genomics Laboratory, Royal Devon & Exeter NHS Foundation Trust, UK.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Oliver Murch.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Individuals who had evaluation or analysis beyond routine clinical care were part of research studies approved by the Cambridge South Research Ethics Committee (10/H0305/83).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Murch, O., Jain, V., Benneche, A. et al. Further delineation of the clinical spectrum of White–Sutton syndrome: 12 new individuals and a review of the literature. Eur J Hum Genet (2021). https://doi.org/10.1038/s41431-021-00961-3

Download citation

Search

Quick links